I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional
(outside the UK) and Australia:

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

EHA 2022

-
Coming soon
10:15 AM
Duration 5mins Vienna, Austria / Virtual (Hybrid)
Roche-Sponsored DLBCL Symposium at EHA2022: Changing Treatment Paradigms: A New Dawn in DLBCL Treatment Showfile
Ulrich Jager, Franck Morschhauser, Laurie Sehn, Michael Dickinson, Bjorn Chapuy

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:30 AM
Duration 15mins Hall C1
Obinutuzumab plus chemotherapy demonstrates long-term benefit over rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: final analysis of the gallium study
Townsend W, Hiddemann W, Buske C, Cartron G, Cunningham D, Dyer MJS, Gribben JG, Phillips E, Dreyling M, Seymour JF, Grigg A, Trotman J,, Lin TY, Hong XN, Klingbiel D, Nielsen TG, Knapp A, Herold M, Marcus R

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 15mins Hall A8
RG6234, a novel GPRC5D T-cell engaging bispecific antibody, induces rapid responses in patients with relapsed/refractory multiple myeloma: preliminary results from a first-in-human trial
Riley CH, Hutchings M, Yoon S-S, Koh Y, Manier S, Facon T, Harrison SJ, Er J, Volzone F, Pinto A, Montes Gaisán C, Ocio EM, Alfonso-Pierola A, Rodríguez Otero P, Offner F, Guidetti S, Corradini P, Titouan C, Hulin C, Touzeau C, Moreau P, Popat R, Leong S, Mazza R, Bröske A-M, Dekhtiarenko I, Helms H-J, Belli S, Vardar T, Fauti T, Eckmann J, Moore T, Schneider M, Jacob W, Weisser M, Carlo-Stella C

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
04:30 PM
Duration 15mins Hall C1
Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥2 prior therapies: pivotal Phase II expansion results
Dickinson M, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, Khan C, Wróbel T, Offner F, Trněný M, Wu S-J, Cartron G, Hertzberg M, Sureda A, Perez-Callejo D, Lundberg L, Relf J, Clark E, Humphrey K, Martin M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 15mins Hall A8
T-cell activation and myeloma cell killing confirm the mode of action of RG6234, a novel GPRC5D T-cell engaging bispecific antibody, in patients with relapsed/refractory multiple myeloma
Dekhtiarenko I, Lelios I, Attig J, Sleiman N, Lazzaro D, Clausen I, Gräfe N, Helms H-J, Schindler E, Belli S, Fauti T, Eckmann J, Umana P, Jacob W, Schneider M, Riley CH, Hutchings M, Yoon S-S, Koh Y, Manier S, Facon T, Harrison SJ, Er J, Volzone F, Pinto A, Montes Gaisán C, Ocio EM, Alfonso-Pierola A, Rodríguez Otero P, Offner F, Guidetti A, Corradini P, Titouan C, Hulin C, Touzeau C, Moreau P, Popat R, Leong S, Mazza R, Carlo-Stella C, Bröske A-M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 15mins Hall Stolz 1-2
Transcriptomic characterization of MRD response and non-response in pts treated with fixed-duration Venetoclax-Obinutuzumab
Al-Sawaf O, Jin HY, Zhang C, Choi Y, Balasubramanian S, Robrecht S, Kotak A, Chang N, Fink A-M, Tausch E, Schneider C, Ritgen M, Kreuzer K-A, Chyla B, Paulson J, Eichhorst B, Jiang Y, Stilgenbauer S, Jiang Y, Hallek M, Fischer K
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
06:00 PM
Duration 5mins Vienna, Austria / Virtual (Hybrid)
Roche-Sponsored FL Symposium at EHA 2022: T-cell Engaging Bispecific Atibodies: A New Era in the Management of Relapsed/Refractory Follicular Lymphoma Showfile
Wendy Osborne, Emmanuel Bachy, Loretta Nastopuil, Georg Hess

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:30 AM
Duration 15mins Hall A8
Venetoclax in Patients With Chronic Lymphocytic Leukemia With 17p Deletion: 6-Year Follow-Up and Genomic Analyses in a Pivotal Phase 2 Trial
Stilgenbauer S, Tausch E, Roberts AW, Davids MS, Eichhorst B, Hallek M, Hillmen P, Schneider C, Schetelig J, Böttcher S, Popovic R, Ghanim MT, Moran M, Sinai WJ, Wang X, Mukherjee N, Chyla B, Wierda WG, Seymour JF
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 15mins Hall A8
Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 5-year results of the randomized CLL14 study
Al-Sawaf O, Zhang C, Robrecht S, Kotak A, Chang N, Fink A-M, Tausch E, Schneider C, Ritgen M, Kreuzer K-A, Chyla B, Eichhorst B, Jiang Y, Stilgenbauer S, Hallek M, Fischer K
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
09:45 AM
Duration 5mins Vienna, Austria / Virtual (Hybrid)
Roche-Sponsored PNH & SCD Symposium at EHA 2022: Advancing C5 Inhibitor Therapy: Paroxysmal Nocturnal Hemoglobinuria and Sickle Cell Disease Showfile
Tahla Munir, Pablo Bartolucci

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar